Applied Optoelectronics Return On Capital Employed Overview

 

 

According to data from Benzinga Pro, during Q2, Applied Optoelectronics (NASDAQ:AAOI) reported sales totaled $52.30 million. Despite a 10.0% increase in earnings, the company posted a loss of $14.46 million. Applied Optoelectronics collected $52.24 million in revenue during Q1, but reported earnings showed a $16.06 million loss.

What Is ROCE?

Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q2, Applied Optoelectronics posted an ROCE of -0.07%.

It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company’s recent performance, but does not account for factors that could affect earnings and sales in the near future.

ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Applied Optoelectronics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For Applied Optoelectronics, a negative ROCE ratio of -0.07% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Analyst Predictions

Applied Optoelectronics reported Q2 earnings per share at $-0.28/share, which beat analyst predictions of $-0.3/share.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Atara Biotherapeutics Announces Expanded Global Tab-cel Partnership With Pierre Fabre Laboratories And Third Quarter 2023 Financial Results; Cash, Cash Equivalents And Short-Term Investments As Of September 30, 2023, Totaled $102.4M

Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel®, including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining MarketsAtara to Receive Additional

ATRA